Treatment options for postherpetic neuralgia include antidepressants, anticonvulsants ( such as gabapentin, pregabalin, or topiramate ), gabapentin enacarbil ( a prodrug of gabapentin ) and topical agents such as lidocaine patches or capsaicin lotion.
12.
Badly written in parts, for example " Palliative care is often needed after postherpetic neuralgia occurs . " Article seems western orientated in parts . talk ) 15 : 49, 19 December 2007 ( UTC)
13.
A randomized controlled trial found that amitriptyline 25 mg per night for 90 days starting within two days of onset of rash can reduce the incidence of postherpetic neuralgia from 35 % to 16 % ( number needed to treat is 6 ).
14.
However, pain is not experienced by all people with CMT . When neuropathic pain is present as a symptom of CMT, it is comparable to that seen in other peripheral neuropathies, as well as postherpetic neuralgia and complex regional pain syndrome, among other diseases.
15.
The Centers for Disease Control and Prevention recommends shingle vaccine for use in people 60 years old and older to prevent shingles, but it is not recommended to treat active shingles or postherpetic neuralgia ( pain after the rash is gone ) once it develops.
16.
Another vaccine, known as zoster vaccine, is simply a larger-than-normal dose of the vaccine used against chickenpox, and is used in older adults to reduce the risk of shingles ( also called herpes zoster ) and postherpetic neuralgia, which are caused by the same virus.
17.
Spinifex Pharmaceuticals reported the results of a phase 2 clinical trial results in which 183 patients with postherpetic neuralgia received either oral EMA401 or placebo for 28 days . Those assigned to the active condition receiving EMA401 reported significantly less postherpetic neuralgia, a chronic neuropathic pain, compared to those in the placebo condition.
18.
Spinifex Pharmaceuticals reported the results of a phase 2 clinical trial results in which 183 patients with postherpetic neuralgia received either oral EMA401 or placebo for 28 days . Those assigned to the active condition receiving EMA401 reported significantly less postherpetic neuralgia, a chronic neuropathic pain, compared to those in the placebo condition.
